A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).

Tim Warneke,Michael R. Kurman,Robert Dreicer,Daniel J. George,Neal D. Shore,William D. Figg,Robert J. Schotzinger,William R. Moore

A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).

2021

Tim Warneke
Michael R. Kurman
Robert Dreicer
Daniel J. George
Neal D. Shore
William D. Figg
Robert J. Schotzinger
William R. Moore

TPS5090Background: PRL-02 is a long-acting IM formulation of a lipophilic abiraterone prodrug being developed for the treatment of patients with metastatic castration-sensitive (mCSPC) and metastat...

Keywords:

Medicine
Internal medicine
Oncology
in patient
Prodrug
Prostate cancer
open label
multicenter study
Abiraterone
Depot

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations